IDEAYA begins Phase 1/2 Part 2 monotherapy expansion of IDE892 in MTAP-deleted pancreatic, lung cancers
IDYA•IDYA•IDYA•IDYA•IDE892 is being positioned as a potential backbone for MTAP-deleted tumors, an area with no approved therapies and meaningful prevalence in pancreatic cancer and NSCLC.
Combination dose escalation continues for IDE892 with IDE397 in MTAP-deleted NSCLC and pancreatic cancer.
The pan-RAS combination first-patient-in is targeted for the second half of 2026.
IDEAYA Biosciences initiated Part 2 monotherapy expansion in its Phase 1/2 trial of IDE892 in MTAP-deleted pancreatic cancer and NSCLC.
No clinical results were presented; the update focused on trial progress and the start of expansion.
The expansion followed dose escalation that reached projected target drug exposure levels, and the maximum tolerated dose has not been reached.
